Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

PIB: Quality control of Ayush drugs

PIB: Budget allocation and utilization of funds under National Ayush Mission

The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal

Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.

Strides receives USFDA approval for Cyclosporine Softgel Capsules

Strides is the first Indian company to get approval for the product.

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Ayush Minister Sonowal inaugurates Ayush Building Complex in Navi Mumbai

Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively